Company Expects Q4 2025 Revenue of $140.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5M, reflecting growth of approximately 13% over the fourth quarter of 2024. Fourth quarter revenue was driven by continued strong growth in Pain Management, Open Ablation and Open AtriClip devices, the company said. Preliminary, unaudited revenue for full year 2025 is expected to be $534.5M, reflecting growth of approximately 15% over full year 2024. Management now expects full year 2025 positive adjusted EBITDA of approximately $57M-$59M, and full year 2025 adjusted loss per share of approximately (21c)-(18c). FY25 consensus calls for a loss per share of (24c) and revenue of $533.31M.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ATRC with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ATRC
Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 51.83 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.770
Low
45.00
Averages
51.83
High
64.00
Current: 37.770
Low
45.00
Averages
51.83
High
64.00
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
Continue Reading
DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
Continue Reading